Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting

Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 
Annual Meeting 
TUSTIN, CA -- (Marketwire) -- 04/01/13 --  Peregrine Pharmaceuticals,
Inc. (NASDAQ: PPHM), a biopharmaceutical company developing
first-in-class monoclonal antibodies focused on the treatment and
diagnosis of cancer, today announced the acceptance of three
preclinical abstracts scheduled for poster presentations at the 104th
Annual Meeting of the American Association for Cancer Research
(AACR), to be held April 6-10, 2013 in Washington, DC. Data to be
presented include studies investigating the immune stimulating
mechanism of action of Peregrine's lead phosphatidylserine
(PS)-targeting oncology clinical candidate bavituximab and the
anti-tumor and imaging potential of other PS-targeting constructs. 
Abstract Details: 
Abstract Number 1244
 Presentation Title:
Phosphatidylserine-targeting antibody reactivates tumor immunity and
destroys tumor vasculature in mice
 Presentation Time: Monday, Apr
08, 2013, 1:00 PM - 5:00 PM EDT
 Location: Hall A-C, Poster Section
5
 Poster Board Number: 24
 Author Block: Yi Yin, Xianming Huang, Dan
Ye, Philip Thorpe. UT Southwestern Medical Ctr., Dallas, TX 
Abstract Number 2850
 Presentation Title: Predicting anti-tumor
responses to phosphatidylserine targeting antibodies using tumor
imaging
 Presentation Time: Tuesday, Apr 09, 2013, 8:00 AM - 12:00 PM
EDT
 Location: Hall A-C, Poster Section 21
 Poster Board Number: 22 
Author Block: Jian Gong(1), Richard Archer(1), Van Nguyen(1),
Christopher C.W. Hughes(2), Jeff Hutchins(1), Bruce Freimark(1). 1.
Peregrine Pharmaceuticals, Inc., Tustin, CA; 2. University of
California, Irvine, Irvine, CA 
Abstract Number: 4326
 Presentation Title:
Phosphatidylserine-targeting 'betabodies' for the treatment of
cancer
 Presentation Time: Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM
EDT
 Location: Hall A-C, Poster Section 36
 Poster Board Number: 9 
Author Block: Xianming Huang(1), Dan Ye(1), Troy Luster(2), E. Sally
Ward(1), Philip Thorpe(1). 1. UT Southwestern Medical Ctr., Dallas,
TX; 2. Human Genome Science, Maryland, MD  
About Peregrine Pharmaceuticals, Inc. 
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative monoclonal antibodies in clinical tr
ials
focused on the treatment and diagnosis of cancer. The company is
pursuing multiple clinical programs in cancer with its lead product
candidate bavituximab and novel brain cancer agent Cotara(R).
Peregrine also has in-house cGMP manufacturing capabilities through
its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com),
which provides development and biomanufacturing services for both
Peregrine and third-party customers. Additional information about
Peregrine can be found at www.peregrineinc.com. 
Contact: 
Christopher Keenan or Jay Carlson 
Peregrine Pharmaceuticals, Inc. 
(800) 987-8256 
info@peregrineinc.com 
 
 
Press spacebar to pause and continue. Press esc to stop.